According to CRI’s market research, the sales value of Anlotinib in the Chinese market increases year by year from 2018 to 2020. Especially in 2019, sales reached CNY 650 million, an increase of about 20 times year on year. The main reason is that Anlotinib has been welcomed by hospitals and patients based on its therapeutic advantages since its approval in 2018. The CAGR of the sales value of Anlotinib in the Chinese market is 444.49% from 2018 to 2020.

CRI predicts that the sales of Rotinib in the Chinese market will continue to grow from 2021 to 2025, with the increase in the number of cancer patients. Lung cancer is the leading cause of human cancer deaths, accounting for about one-fifth of all cancer deaths. According to the data on the number of new cancers in 2020 released by WHO, the number of new lung cancers and deaths in China in 2020 is 280,000 and 710,000, respectively, which are the highest in the world. Anlotinib-treated non-small cell lung cancer (NSCLC) accounts for 80% to 90% of lung cancer in China. The huge patient population will continue to expand the market of Anlotinib. In addition, the increase in indications will also increase sales. In the first half of 2021, Focavi’s fourth indication is in the state of approval in China. It is expected that with the approval of new indications in the future, the patient population of Anlotinib will expand, and sales value and sales volume will also increase to a certain extent.

Topics Covered:
-The impact of COVID-19 on China’s Anlotinib market
– Sales value of China’s Anlotinib 2016-2020
– Competitive landscape of China’s Anlotinib market
– Prices of Anlotinib in China
– Prices of Anlotinib in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Anlotinib market
– Prospect of China’s Anlotinib market from 2021 to 2025

The post Investigation Report on China’s Anlotinib Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Doxorubicin in the Chinese market has increased year by year from 2016 to 2020. Especially, the sales of Doxorubicin in the Chinese market reached CNY 855 million in 2019, a year-on-year increase of 69.75%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the growth rate of Doxorubicin’s sales value in the Chinese market has declined, but the sales still reached about CNY 1 billion in 2020. The CAGR of Doxorubicin’s sales value in the Chinese market is 38.60% from 2016 to 2020.

CRI expects that with the increase of cancer patients in 2021-2025, the sales volume of Doxorubicin in the Chinese market will increase steadily. Doxorubicin liposome injection has the advantages of targeting, sustained release, and reduced toxicity. Based on these advantages, the sales volume and sales of Doxorubicin liposome injection will continue to increase. In addition, the alleviation of the COVID-19 epidemic will also cause the sales of Doxorubicin to show a recovery growth.

Topics Covered:
-The impact of COVID-19 on China’s Doxorubicin market
– Sales value of China’s Doxorubicin 2016-2020
– Competitive landscape of China’s Doxorubicin market
– Prices of Doxorubicin in China
– Prices of Doxorubicin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Doxorubicin market
– Prospect of China’s Doxorubicin market from 2021 to 2025

The post Investigation Report on China’s Doxorubicin Market 2021-2025 first appeared on CRI Report.

Topics Covered:
-The impact of COVID-19 on China’s Levofloxacin market
– Sales value of China’s Levofloxacin 2016-2020
– Competitive landscape of China’s Levofloxacin market
– Prices of Levofloxacin in China
– Prices of Levofloxacin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Levofloxacin market
– Prospect of China’s Levofloxacin market from 2021 to 2025

The post Investigation Report on China’s Levofloxacin Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Goserelin in the Chinese market has increased year by year since 2016-2020, with the CAGR from 2016 to 2019 is around 18%. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of Chinese hospitals, the annual growth rate of Goserelin’s sales value dropped to 8.76% in 2020. However, the sales value of Goserelin in the Chinese market reached CNY990 million in 2020 and the CAGR of the sales value of Goserelin in the Chinese market is 15.94% from 2016 to 2020.

CRI predicts that with the increase in the number of patients with indications, the sales volume of Goserelin will steadily increase from 2021 to 2025. In 2020, the number of new breast cancers worldwide reached 2.26 million, and the number of prostate cancers was 1.41 million, both of which were on the rise. Therefore, the sales volume of Goserelin for the treatment of breast cancer and prostate cancer increased with the increase in the number of patients diagnosed with breast cancer and prostate cancer, and its sales also increased. China has approved Luye Pharmaceuticals to conduct generic drug clinical trials and has successfully conducted Phase III clinical trials at the end of 2020. It is expected that the generic drug will be launched in the next five years. As a result, the price of Goserelin will continue to fall, sales and sales volume will also have certain upside potential. In addition, the effective alleviation of COVID-19 will also cause a recovery growth in the sales of Goserelin.

Topics Covered:
-The impact of COVID-19 on China’s Goserelin market
– Sales value of China’s Goserelin 2016-2020
– Competitive landscape of China’s Goserelin market
– Prices of Goserelin in China
– Prices of Goserelin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Goserelin market
– Prospect of China’s Goserelin market from 2021 to 2025

The post Investigation Report on China’s Goserelin Market 2021-2025 first appeared on CRI Report.

According to CRI’s research market, the sales of Hydrotalcite in the Chinese market were generally stable from 2016 to 2019. The sales value of Hydrotalcite in the Chinese market decreased by 49.28% year on year because of the outbreak of the COVID-19 epidemic in 2020 and the effects of government procurement. The CAGR of China’s Hydrotalcite sales value from 2016 to 2020 is -15.36%.

CRI predicts that the sales of Hydrotalcite in China will have a restorative growth from 2021 to 2025 as the alleviation of the COVID-19 epidemic. In addition, in the context of an aging population and unhealthy lifestyles, the number of patients with gastrointestinal diseases in China will continue to increase, and the sales value and sales volume of Hydrotalcite used to treat acute and chronic gastroenteritis and other gastrointestinal diseases will increase. It is estimated that China’s Hydrotalcite sales market by sales value will exceed CNY100 million.

Topics Covered:
-Development environment of Chinese Hydrotalcite market
-Governmental approval of Hydrotalcite in China
-Prices of Hydrotalcite in China
-Major Hydrotalcite manufacturers in China
-Factors influencing the development of Chinese Hydrotalcite market
-Prospects of Chinese Hydrotalcite market

The post Investigation Report on China’s Hydrotalcite Market, 2021-2025 first appeared on CRI Report.

According to CRI’s analysis, the efficiency and functions of express delivery services are better than ordinary postal services in China, but the charges are also significantly higher than ordinary postal services. There are three types of courier services: intra-city courier, domestic inter-city courier, and international courier.

In 2020, China’s online retail sales value reached CNY11,760.1 billion, with a year-on-year increase of 10.9%. Among them, the online retail sales value of physical goods was CNY975.9 billion, with an increase of 14.8%, accounting for 24.9% of the total retail sales of consumer goods; among the online retail sales of physical goods, food, clothing, and consumer goods increased by 30.6% and 5.8% and 16.2% respectively.

According to CRI’s analysis, the rapid rise of e-commerce in China in recent years and the surge in market demand have led to rapid growth in the express delivery industry. The volume of China’s express delivery business has increased from 31.3 billion in 2016 to 83.4 billion in 2020. In 2020, the revenue of China’s express delivery industry has reached CNY879.5 billion. The Chinese government has issued a series of policies to support the development of the express delivery industry, and some local governments have also issued policies to support the development of the express delivery industry in the region. However, the development of China’s express delivery industry also has some risks and challenges, such as rising rents and labor costs leading to an increase in overall costs. And some government policies may also have an adverse effect on China’s express delivery industry.

Due to the extensive development of China’s express delivery industry, severe homogeneity competition, the continued decline in profit margins, and capital needs of large infrastructure, many private express companies that have difficulty in obtaining bank loans have chosen to be listed to raise funds to increase their competitive advantage in the market. By 2020, the market structure of China’s express delivery industry has not undergone major changes. Major companies in the express industry have been listed. For example, Zhongtong Express and Best Express are listed on the New York Stock Exchange. S.F. Holding Co., Ltd., YTO Express, STO Express, and Yunda Express with their backdoor listing plan are listed on the A-share market. Debon, as the first express company to be listed on the domestic main board through an IPO, is listed on the A-share market.

According to CRI’s analysis, due to rising labor costs and store rents in China, the cost of physical stores has continued to rise, enhancing the advantages of the online retail industry. It is expected that China’s e-commerce industry will develop rapidly from 2021 to 2025. In addition, due to the severe impact of the COVID-19 epidemic on the real economy in 2020, the advantages of e-commerce have become prominent, driving the rapid development of the express delivery industry. At the same time, new e-commerce models such as cross-border shopping will also promote the development of China’s express delivery industry and bring new development directions to the express delivery industry. The policies of the Chinese government in the next few years will also be beneficial to the development of the express delivery industry. For example, the State Council executive meeting held in 2021 has determined a series of measures to support transportation, express delivery, and other logistics industries to alleviate difficulties and speed up the recovery and development. These include that all localities should provide equal access to postal and express delivery companies of various ownerships, break the “last mile” delivery barriers in villages and communities and increase reductions of the tax fee.

Topics Covered:
-Economic Environment of Express Delivery Industry in China
-Policies in Express Delivery Industry in China
-Analysis of Supply and Demand in Express Delivery Industry in China, 2016-2020
-Analysis of Market Competition in Express Delivery Industry in China
-Analysis of Major Companies in Express Delivery Industry in China
-Analysis of Costs in Express Delivery Industry in China
-Price Trend of Express Delivery Services in China
-Driving Forces and Opportunities in Express Delivery Industry in China
-Unfavorable Factors in Express Delivery Industry in China
-Forecast on Supply and Demand in Express Delivery Industry in China 2020-2024
-The impact of COVID-19 on the Express Delivery Industry in China

The post Investigation Report on China’s Express Delivery Industry 2021-2025 first appeared on CRI Report.

MOSFET is an acronym for Metal Oxide Semiconductor Field Effect Transistor, also known as MOS, MOS transistor. The name “metal–oxide–semiconductor” (MOS) typically refers to a type of insulated-gate field-effect transistor that is fabricated by the controlled oxidation of a semiconductor, typically silicon.

It is a power semiconductor that is used as an electronic switch device to control the loads as per requirement. As the most basic electronic device, MOSFET has the characteristics of high frequency, voltage drive, and good resistance to breakdown. Its application covers power supplies, inverters, CPU and graphics cards, communications, consumer electronics, automotive electronics, industrial systems, and other fields.

In 2020, the revenue of global MOSFET Market revenue is about USD 8.6 billion, and CAGR from 2016 to 2020 is about 10%. In 2020, the sales value of China’s MOSFET industry was approximately CNY 24.5 billion, with an increase of approximately 25.7% year-on-year, which is the highest in the past five years.

The main reason is that the COVID-19 epidemic in 2020 has dealt a blow to MOSFET and its upstream market, resulting in a general increase in MOSFET prices by about 10% to 20%. Also, the development of new energy vehicles in China has stimulated the demand for MOSFET. From 2016 to 2020, MOSFET sales in China have increased year by year, with a CAGR of about 19%.

According to CRI’s analysis, the power semiconductor Market to which MOSFET belongs has developed vigorously in recent years, and sales of MOSFET have increased in the semiconductor market year by year due to the advantages of stability and efficiency.

However, Chinese MOSFET companies account for less than 40% of China’s MOSFET market due to technological backwardness and other reasons. Therefore, China’s MOSFET mainly relies on foreign-funded enterprises and imports.

In recent years, the main driving force for the growth of China’s MOSFET market has come from new energy vehicles, consumer electronics, industries, home appliances, aerospace, and other market segments. China is the world’s largest automobile producer and consumer.

Also, China is the world’s largest electronic product manufacturing base, and the world’s largest manufacturing OEM base. It is expected that China will remain the world’s largest MOSFET consumer market for a long time into the future and the market scale will continue to grow.

In 2020, the output of new energy vehicles (electric vehicles) reached 1.456 million, with an increase of approximately 22% year-on-year. With the rapid increase in China’s new energy vehicle production, the automotive sector has become an important driving force for the growth of China’s MOSFET market.

In addition, in recent years, as China’s labor costs continue to rise, the increase in the level of automation has become an inevitable choice for China’s manufacturing market. The growing demand of the Chinese market for industrial automation equipment, such as CNC machine tools and industrial robots, has stimulated the demand for MOSFET.

At the same time, with the rise of China’s informatization level, the Internet of things market is developing rapidly, and the demand for smart cities, smart logistics, industrial monitoring is constantly increasing. According to CRI’s research market, the scale of China’s Internet of things market reached about CNY 1.8 trillion in 2020. The demand for MOSFET in the Chinese Internet of things market is also rising rapidly.

Topics covered:
Status of global MOSFET Market
Chinese government’s supportive policies on MOSFET Market
Supply of MOSFET
Analysis of Market demand for MOSFET
Major MOSFET enterprises in China
Analysis of import and export of MOSFET in China
Threats and challenges to MOSFET Market
Prospect of MOSFET Market from 2021 to 2025
Impact of the Sino-U.S. trade war on MOSFET Market
Impact of COVID-19 on MOSFET Market

The post Investigation Report on Global and China’s MOSFET Market 2021-2025 first appeared on CRI Report.

According to CRI analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019. In 2020, due to the impact of the COVID-19 epidemic on the hospital’s overall diagnosis and treatment services, the sales value of Enteral Nutrition in China fell slightly, reached CNY1.155 billion in 2020. The CAGR of the sales value of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.

CRI expects that with the effective relief of the COVID-19 epidemic, the sales of Enteral Nutrition in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Enteral Nutrition is widely used clinically. With the improvement and popularization of medical services in China, the demand for Enteral Nutrition will continue to increase, so the sales of Enteral Nutrition in China will maintain a growing trend.

Topics Covered:
-The impact of COVID-19 on China’s Enteral Nutrition market
– Sales value of China’s Enteral Nutrition 2016-2020
– Competitive landscape of China’s Enteral Nutrition market
– Prices of Enteral Nutrition in China
– Prices of Enteral Nutrition in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Enteral Nutrition market
– Prospect of China’s Enteral Nutrition market from 2021 to 2025

The post Investigation Report on China’s Enteral Nutrition Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Insulin Glargine has shown an upward trend from 2016 to 2020 in China, reaching CNY960.49 million in 2020. Sales growth in 2020 has slowed down compared to previous years. The main reason is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.

CRI predicts that from 2021 to 2025, the sales of Insulin Glargine in China will have a recovery growth with the improvement of the epidemic and the normal operation of the hospital’s overall diagnosis and treatment business. In addition, its sales will also increase due to market expansion. The number of diabetic patients in China has ranked the first in the world, and there is a great demand for diabetes treatment drugs. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance, and duration of action, indicating that the Insulin Glargine market has room for growth in China. In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future. Therefore, the price of Insulin Glargine is expected to continue to fall, driving sales volume to increase sales.

Topics Covered:
-The impact of COVID-19 on China’s Insulin Glargine market
– Sales value of China’s Insulin Glargine 2016-2020
– Competitive landscape of China’s Insulin Glargine market
– Prices of Insulin Glargine in China
– Prices of Insulin Glargine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Insulin Glargine market
– Prospect of China’s Insulin Glargine market from 2021 to 2025

The post Investigation Report on China’s Insulin Glargine Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales value of Emtricitabine/Tenofovir in the Chinese market has increased year by year from 2016 to 2019, with a decline in 2020. The main reason for this decline is that the COVID-19 epidemic has affected the overall diagnosis and treatment business of the hospital. At the beginning of 2017, Emtricitabine/Tenofovir was included in China’s Medical Insurance, so its sales value grew rapidly to CNY10.86 million in 2018, with an annual growth rate of 103%. The sales value of Emtricitabine/Tenofovir in the Chinese market reached CNY16.43 million in 2020 and the CAGR is 35.4% from 2016 to 2020, which is a very high level.

CRI predicts that with the increase in the number of AIDS patients in China, the sales of Emtricitabine/Tenofovir will also increase from 2016 to 2019. In 2019, the number of surviving HIV infections in China reached 958,000. In 2020, the number of surviving AIDS infections in China increased to 1.045 million, with an increase of 9%. The number of new infections will still show an increasing trend in the future. How to prevent new HIV infections has become the key to prevent and control the spread of AIDS. Therefore, sales in Emtricitabine/Tenofovir of the preventive HIV drugs will continue to increase. By 2020, 2 companies have launched generic versions of Truvada (Emtricitabine/Tenofovir) in China. The generic version from Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the first Chinese-made HIV combination tablet in the country. Qilu Pharmaceutical and Hisco Pharmaceutical are waiting for an Abbreviated New Drug Application (ANDA) approval for their generic version, and they will compete for the market after approval. The market competition of Emtricitabine/Tenofovir in China will become more intense. Sales prices are expected to continue to fall, and sales volume will increase accordingly. In addition, the effective alleviation of the COVID-19 epidemic during the period of 2021-2025 will also enable the sales of Emtricitabine/Tenofovir to have restorative growth.

Topics Covered:
-The impact of COVID-19 on China’s Emtricitabine/Tenofovir market
– Sales value of China’s Emtricitabine/Tenofovir 2016-2020
– Competitive landscape of China’s Emtricitabine/Tenofovir market
– Prices of Emtricitabine/Tenofovir in China
– Prices of Emtricitabine/Tenofovir in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Emtricitabine/Tenofovir market
– Prospect of China’s Emtricitabine/Tenofovir market from 2021 to 2025

The post Investigation Report on China’s Emtricitabine/Tenofovir Market 2021-2025 first appeared on CRI Report.